Carbidopa
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Carbidopa Product Information
Carbidopa is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Carbidopa. The product is supplied by Clearsynth under CAT No. CS-O-01054.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Carbidopa
CAS No.
28860-95-9
CAT No.
CS-O-01054
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C10H14N2O4
Molecular Weight
226.23
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Carbidopa is supplied with detailed characterization data compliant with regulatory guideline. Carbidopa can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Carbidopa.
Overview
(S)-(-)-Carbidopa is a peripheral decarboxylase inhibitor that is commonly used in combination with L-DOPA for treatment of Parkinsonism. S(-)-Carbidopa ( has also been shown to prolong the elimination half-life of L-DOPA from blood plasma
Synonyms
Carbidopa
Application Notes
(S)-(-)-Carbidopa is a peripheral decarboxylase inhibitor that is commonly used in combination with L-DOPA for treatment of Parkinsonism. S(-)-Carbidopa ( has also been shown to prolong the elimination half-life of L-DOPA from blood plasma
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.